InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.290

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$89 Successful Completion of Share Purchase Plan 5 Aug 2024 9:28AM $0.465 $0.290 fallen by 37.63%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 26 Jul 2024 10:44AM $0.460 $0.290 fallen by 36.96%
$89 US Department of Defense Grants US $2m for R327G 15 Jul 2024 9:50AM $0.460 $0.290 fallen by 36.96%
$89 Change of Auditor 11 Jul 2024 3:25PM $0.465 $0.290 fallen by 37.63%
$89 Share Purchase Plan - Letter and Offer Booklet 10 Jul 2024 9:37AM $0.465 $0.290 fallen by 37.63%
$89 Cleansing Notice 9 Jul 2024 10:05AM $0.460 $0.290 fallen by 36.96%
$89 Application for quotation of securities - RCE 9 Jul 2024 9:59AM $0.460 $0.290 fallen by 36.96%
$89 R327 Efficacy against WHO Priority Pathogen Acinetobacter B 8 Jul 2024 9:53AM n/a $0.290 n/a
$89 Equity Raising Presentation 2 Jul 2024 10:25AM $0.600 $0.290 fallen by 51.67%
$89 Proposed issue of securities - RCE 2 Jul 2024 10:23AM $0.600 $0.290 fallen by 51.67%
$89 Placement & SPP to raise $10 million - Funded to FY26 2 Jul 2024 10:23AM $0.600 $0.290 fallen by 51.67%
$89 Trading Halt 1 Jul 2024 9:33AM $0.600 $0.290 fallen by 51.67%
$89 Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial 1 Jul 2024 9:07AM $0.600 $0.290 fallen by 51.67%
$89 Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete 28 Jun 2024 9:21AM $0.570 $0.290 fallen by 49.12%
$89 Ethics Approval Broadens to All Topical Infections 24 Jun 2024 9:55AM $0.575 $0.290 fallen by 49.57%
$89 Further R&D Rebate Approved 18 Jun 2024 2:40PM $0.583 $0.290 fallen by 50.21%
$89 R327 added to WHO List of Antibacterial Products 18 Jun 2024 10:04AM $0.550 $0.290 fallen by 47.27%
$89 Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial 11 Jun 2024 8:39AM $0.565 $0.290 fallen by 48.67%
$89 Military Health Research Symposium Abstract & Presentation 3 Jun 2024 9:57AM $0.585 $0.290 fallen by 50.43%
$89 Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort 15 May 2024 11:46AM $0.615 $0.290 fallen by 52.85%
$89 Cleansing Statement 10 May 2024 6:14PM $0.640 $0.290 fallen by 54.69%
$89 Application for quotation of securities - RCE 10 May 2024 6:06PM $0.640 $0.290 fallen by 54.69%
$89 MCRI Pilot Study- Positive Efficacy Data for Lung Infections 9 May 2024 12:31PM $0.645 $0.290 fallen by 55.04%
$89 China Patent Granted for RECCE Anti-Infectives 7 May 2024 8:38AM $0.660 $0.290 fallen by 56.06%
$89 Safety Committee Approves High Dose of 4,000mg 26 Apr 2024 9:42AM $0.685 $0.290 fallen by 57.66%

151 - 175 of 735 results

Page 7 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.